Tesla (NASDAQ:TSLA) reported first-quarter delivery numbers that fell short of Wall Street expectations, raising fresh concerns about a widening gap between the electric vehicle maker's manufacturing pace and global consumer appetite.
Innovative Aerosystems (NASDAQ:ISSC) has reached an agreement with Honeywell International (NASDAQ:HON) to acquire key assets and intellectual property for select legacy avionics lines, a move that deepens the company’s reach into the global general aviation market.
Merck (NYSE:MRK) has secured a landmark regulatory approval in the European Union for its blockbuster immunotherapy Keytruda, marking the region’s first PD-1 inhibitor authorized to treat a particularly aggressive form of ovarian cancer.
Adagene (NASDAQ:ADAG) reported updated clinical data for its lead "SAFEbody" candidate, muzastotug, revealing a significant dose-dependent response in patients with treatment-resistant colorectal cancer—a population that has traditionally been unresponsive to immunotherapy.
Classover (NASDAQ:KIDZ), an AI-powered education technology company, reported its full-year 2025 financial results.
Namib Minerals (NASDAQ:NAMM) reported a resilient fiscal 2025 performance, characterized by rising profitability and steady progress on its multi-asset growth strategy in Zimbabwe, despite a slight dip in annual gold production.
ScottsMiracle-Gro (NYSE:SMG) has reaffirmed its fiscal 2026 financial guidance, signaling confidence in its margin recovery plan by highlighting a supply chain largely insulated from international volatility and inflationary spikes.
Adagene (NASDAQ:ADAG) and Incyte (NASDAQ:INCY) have entered into a clinical trial collaboration to evaluate a potent combination of immunotherapy agents in patients with microsatellite stable colorectal cancer (MSS CRC), a disease state notoriously resistant to standard immune checkpoint inhibitors.
AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.
Pharvaris (NASDAQ:PHVS) is moving toward its first regulatory filing in the first half of 2026, supported by a strong cash position and pivotal clinical successes for its lead candidate, deucrictibant.
Merck (NYSE:MRK) has officially moved its lead ophthalmology candidate into late-stage development, initiating a pivotal Phase 2b/3 trial for MK-8748 just two years after the pharmaceutical giant’s $3 billion acquisition of EyeBio.
Lindsay (NYSE:LNN) reported a sharp decline in second-quarter profitability as a contraction in both its agricultural and infrastructure segments weighed on the top line, leading to a more than 50% drop in net earnings.
-640x360.webp&w=3840&q=75)
